This is a double blind study of an oral agent to be used in the treatment of Alzheimer's Disease. It is a multicenter, parallel group, placebo controlled study of safety and efficacy at doses of 25,50 or 75 mgm TID in patients with mild to moderate dementia.
Showing the most recent 10 out of 1103 publications